Medical Affairs is moving from “science conduit” to decision partner - a role that asks Medical Science Liaisons (MSLs) to spot real-world signals, turn them into timely actions, and explain numbers so clinicians and patients actually change what they do next (1,2). The good news: you do not need a data lake or a PhD in artificial intelligence (AI) to start; what you need is a … [Read more...]

Lessons from the Best MSLs Around the Globe As a member of the judging panel for the Medical Science Liaison Society (MSLS) Awards, I had the opportunity to thoroughly review and evaluate the submissions from candidates aspiring to be recognized among the best MSLs worldwide. Based on this experience, the present document analyzes a series of testimonies and perspectives … [Read more...]

Introduction Imagine this: you walk into a meeting with a leading Key Opinion Leader (KOL). This person barely looks up from his phone, nods while you speak, and leaves you wondering—did my message even land? The very next day, you’re facing a player who insists on cost-effectiveness data, followed by a Digital Opinion Leader DOL asking for a visual summary he can share on … [Read more...]

For many of us who transition into the Medical Science Liaison (MSL) role from commercial backgrounds, there’s a moment of deliberate recalibration. We learn to set aside the language of “sales targets” and “prescription volume” and embrace the principles of non-promotional, scientific exchange. This is not just a necessary shift; it is the very foundation of our credibility … [Read more...]

Introduction Cangrelor is an intravenous P2Y12 inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis. [1] Cangrelor provides immediate platelet inhibition (onset within 2 minutes following administration of a 30 mcg/kg IV bolus, … [Read more...]

Disclaimer: This article was developed with the assistance of generative AI tools. Abstract Clinicians—nurse practitioners, physician associates, pharmacists, and physicians—are uniquely equipped to lead in Medical Science Liaison (MSL) roles because they bring the human experience of care into the science of communication. This editorial explores how the clinical mindset, … [Read more...]

In today’s data-driven healthcare landscape, the value of a therapy extends far beyond its efficacy in clinical trials. Payers, policymakers, and healthcare providers increasingly demand evidence that demonstrates real-world value. This shift has placed Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) at the heart of medical strategy. We explore … [Read more...]

Introduction Medical Science Liaisons (MSLs) have established themselves as trusted partners to healthcare professionals (HCPs), with 58% of HCPs rating MSL interactions as more valuable than those with sales representatives—and an additional 18% rating them as much more valuable. However, trust in itself is insufficient as MSLs encounter growing demands to provide … [Read more...]

Purpose and Context Regional scientific conferences serve as accessible, cost-effective venues for fostering meaningful scientific exchange among healthcare professionals (HCPs). When Medical Science Liaisons (MSLs) participate in Medical Affairs booths at these events, they play a pivotal role in building local connections, facilitating evidence-based conversations, and … [Read more...]

The importance of being E.. xplorative! The transition from pharmaceutical sales to Medical Science Liaison represents more than a career move; it’s a transformation that demands curiosity, dedication, and the courage to step into an undefined role. My journey began when the company I was working for at that time decided to create its first MSL positions, selecting specialty … [Read more...]

INTRODUCTION: In these times of rapid discovery, it is vital to remember five bioethical foundations undergirding all beneficial medical research. These foundations (summarized by the acronym BNAIJ) are beneficence, nonmaleficence, autonomy, informed consent/assent, and justice. Others have written more detailed explanations of these foundations. However, this primer is … [Read more...]

Diagnostic delay is one of the biggest challenges in managing rare diseases. For example, narcolepsy patients often wait between 8 to 15 years from the onset of symptoms to receiving a proper diagnosis. This delay can severely disrupt their education, jobs, and mental health (Carter LP et al., Postgrad Med 2014; 126(3): 216-24). Closing this gap requires more than just … [Read more...]

For decades, agencies under the U.S. Department of Health and Human Services (HHS) were regarded as the gold standard for medical and scientific guidance. Healthcare professionals (HCPs) trusted these agencies to provide reliable, evidence-based recommendations that shaped clinical practice standards and public health interventions. As federal health agencies face mounting … [Read more...]

The Missing Ingredient in Scientific Success In a profession that thrives on evidence, reproducibility, and rigor, one variable remains under-measured but over-influential: culture. For Medical Science Liaison (MSL) teams and broader life-science organizations, culture is not a soft metric — it’s the hidden force that determines how knowledge flows, how people behave under … [Read more...]